Molecular testing provides fast and accurate results and the prescence of molecular tests has disrupted several testing markets over the past decade and a half. However, some segments have thrived and others are seeing mature growth levels.
This report details the highest revenue growth areas of molecular testing, as considered by manufacturers of IVD instruments, reagents and supplies. The report covers both high-growth product segments and regional markets of significance.
Expected High Growth Market Segments in Molecular Diagnostic Testing Provides:
High-Growth Areas in Molecular Infectious Disease Testing
High-Growth Areas in Molecular Cancer Testing
High-Growth Areas in Other Molecular Testing
High-Growth Regions
Overview of Molecular Test Technologies.
Top Companies in High-Growth Molecular Testing Markets
Conclusions and Projections to 2021
Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices.
The report also covers Inherited disease diagnostics - diagnosis of rare genetic diseases andother inherited traits including pharmacodiagnostic (pharmacokinetic) traits;major area of application is thrombophilia markers and anticoagulant response markers.
Coverage in this report includes:
Infectious disease diagnostics such as molecular microbiology and virology, including the detection, identification, quantification and nucleic-acid based resistance or susceptibility profiling of pathogens
Blood Transfusion Diagnostics, nucleic acid screening (NAT) of donated blood, often pooled samples, for the detection of active infections responsible for transfusion transmitted infections (TTIs)
ancillary market for molecular immunohematology or blood typing
Histology / cytology diagnostics , which is largely synonymous with in situ hybridization (ISH) methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) nucleic acid probes within slided tissue or suspended cell samples viewed under microscopy;Molecular Cancer Diagnostics, which are tissue, blood and urine samples can be assayed using nucleic acid amplification tests (NAATs) or sequencing to diagnose, prognose and identify key mutations for targeted therapies
future
Transplant diagnostics - various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, as well as post-transplant monitoring.
Key Topics Covered:
1: Executive Summary
Introduction Molecular Diagnostic Technologies Molecular Diagnostics in Healthcare
HIGH GROWTH AREAS OF MOLECULAR DIAGNOSTICS HIGH-GROWTH REGIONAL MARKETS
2: Analysis: High-Growth Markets For Molecular Diagnostics
HIGH REVENUE GROWTH MOLECULAR TESTING AREAS IDENTIFIED High Growth Categories in the Infectious Disease Molecular Diagnostics Market Market Size in 2016 and Forecast to 2021 High-Growth Regions for Infectious Disease Diagnostics Market (2016-2021) High Growth Infectious Disease Market Area High Growth Regions, NAT Blood Screening Market Market Size 2016 and Forecast to 2021 High Growth Cancer Market Area High Growth Cancer Testing Areas, Market Size 2016 and Forecast 2021 Molecular Cancer Testing High Growth Regions High Growth Cancer Testing Regional Markets Other Molecular Testing High-Growth Areas, Market Size 2016 and Forecast 2021 High Growth Regional Markets for Other Testing High-Growth Regional Markets for Other Molecular Diagnostics Testing
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...